Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Aktis Oncology is raising $84,000,000.00 in new funding. Sources indicate as part of senior management Chairman, Todd Foley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aktis Oncology
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncologys molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

To learn more about Aktis Oncology, visit http://www.aktisoncology.com/

Contact:
Todd Foley, Chairman
617-461-4023
tfoley@aktisoncology.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved